Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,960.00GBp
18 Jan 2018
Change (% chg)

-30.50 (-0.61%)
Prev Close
4,990.50
Open
5,004.00
Day's High
5,015.00
Day's Low
4,938.50
Volume
544,734
Avg. Vol
2,403,505
52-wk High
5,585.07
52-wk Low
4,136.50

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Cambrex & Astrazeneca Hold Ceremony To Mark Long-Term Supply Agreement At Karlskoga, Sweden Facility

* CAMBREX & ASTRAZENECA HOLD CEREMONY TO MARK LONG-TERM SUPPLY AGREEMENT AT KARLSKOGA, SWEDEN FACILITY Source text for Eikon: Further company coverage:

16 Jan 2018

U.S. FDA approves expanded use of AstraZeneca cancer drug

The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.

12 Jan 2018

FDA approves expanded use of AstraZeneca cancer drug

The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.

12 Jan 2018

UPDATE 1-U.S. FDA approves expanded use of AstraZeneca cancer drug

Jan 12 The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.

12 Jan 2018

U.S. FDA approves expanded use of AstraZeneca breast cancer drug

Jan 12 The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.

12 Jan 2018

BRIEF-Astrazeneca Says ‍Fasenra Receives EU Approval

* ‍FASENRA RECEIVES EU APPROVAL FOR SEVERE EOSINOPHILIC ASTHMA​

10 Jan 2018

BRIEF-Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca

* MYRIAD GENETICS ANNOUNCES EXPANDED RESEARCH COLLABORATION WITH ASTRAZENECA

03 Jan 2018

BRIEF-Almirall Signs Distribution Agreement With AstraZeneca For Crestor And Provisacor In Spain

* EXECUTES LICENSE AND SUPPLY AGREEMENT WITH ASTRAZENECA FOR CRESTOR AND PROVISACOR (ROSUVASTATIN)

22 Dec 2017

BRIEF-Astrazeneca Says ‍US FDA Updates Symbicort Label With Laba Safety Class Revisions

* ‍US FDA UPDATES SYMBICORT LABEL WITH LABA SAFETY CLASS REVISIONS AND REMOVES BOXED WARNING FOR SERIOUS ASTHMA-RELATED OUTCOMES​

21 Dec 2017

BRIEF-Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060

* PIERIS PHARMACEUTICALS-DOSED FIRST SUBJECTS IN PHASE I STUDY OF PRS-060, TRIGGERING $12.5 MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO CO-SEC FILING Source text: (http://bit.ly/2oXTLTa) Further company coverage:

20 Dec 2017

Earnings vs. Estimates